Benitec Biopharma (BNTC) Cash & Equivalents (2019 - 2025)

Benitec Biopharma has reported Cash & Equivalents for 7 years, with the latest figure at $188.8 million in Q4 2025.

• Quarterly Cash & Equivalents rose 141.18% year-over-year to $188.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $188.8 million (up 141.18% YoY) and the FY2025 annual result came in at $97.7 million, up 92.16% from the prior year.
• Cash & Equivalents improved to $188.8 million in Q4 2025 per BNTC's latest filing, from $94.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $188.8 million in Q4 2025 and troughed at $2.5 million in Q2 2023.
• A 5-year average of $44.0 million and a median of $19.8 million in 2021 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents sank 79.45% in 2022, then jumped 1953.53% in 2024.
• Over 5 years, Cash & Equivalents stood at $12.3 million in 2021, then declined by 14.53% to $10.5 million in 2022, then jumped by 93.36% to $20.4 million in 2023, then jumped by 284.23% to $78.3 million in 2024, then jumped by 141.18% to $188.8 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $188.8 million, $94.5 million, and $97.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.